Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Deamicis

Internal Medicine Chelmsford, MA Medical Doctor

NPI 1801865233 CMS profile 263042

4 Courthouse Ln, Suite 9, Chelmsford, MA 01824

Open in the dashboard

General payments

$4,381

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Deamicis of Chelmsford, MA is reported in the CMS Open Payments database as having received $4,381 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $684 29
2024 General $572 25
2023 General $521 28
2022 General $526 29
2021 General $970 53
2020 General $677 34
2019 General $431 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Deamicis
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Deamicis were reported at $684. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Deamicis Internal Medicine median Middle half National median
2019 $431 $159 $48–$570 $163
2020 $677 $119 $33–$402 $114
2021 $970 $135 $37–$521 $132
2022 $526 $141 $42–$496 $149
2023 $521 $149 $45–$519 $160
2024 $572 $154 $47–$537 $164
2025 $684 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $787 56 payments
  2. Pfizer Inc. $505 24 payments
  3. AbbVie, Inc. $494 31 payments
  4. Astellas Pharma US Inc $323 9 payments
  5. AstraZeneca Pharmaceuticals LP $278 15 payments
  6. Amgen Inc. $217 11 payments
  7. Novo Nordisk Inc $213 12 payments
  8. Janssen Pharmaceuticals, Inc $148 6 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $146 7 payments
  10. Abbott Laboratories $141 7 payments
  11. Other $1,129 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,151 229 payments
  2. Education $230 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $452 33 payments
  2. UBRELVY $379 21 payments
  3. XARELTO $274 10 payments
  4. ANORO ELLIPTA $205 10 payments
  5. ELIQUIS $169 7 payments
  6. NURTEC ODT $154 7 payments
  7. CHANTIX $140 7 payments
  8. RYBELSUS $130 8 payments
  9. ZAVZPRET $117 5 payments
  10. QULIPTA $112 5 payments
  11. Other $3,146 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 151 drugs

Part D claims

9,422

Median for Internal Medicine: 777

Drug cost

$590,787

Median for Internal Medicine: $73,373

Branded share of claims

15.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 126 $126,619
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 83 $77,016
Januvia Sitagliptin Phosphate Brand 42 $28,774
Rybelsus Semaglutide Brand 11 $26,396
Ozempic Semaglutide Brand 26 $25,525
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 24 $24,146
Jardiance Empagliflozin Brand 11 $17,895
Mounjaro Tirzepatide Brand 11 $17,863
Myrbetriq Mirabegron Brand 24 $17,122
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $17,091

The 10 drugs with the highest cost, of 151 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$95,943

Of which drugs: $71

Medicare patients

323

Average age 75

Services billed

1,066

159 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 28%
Depression 26%
Ischemic heart disease 23%
Chronic kidney disease 23%
Heart failure 22%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Scientific Affairs, LLC $105
$105 — —
Wegovy
  • Novo Nordisk Inc $39
$39 — —
NURTEC ODT
  • PFIZER INC. $32
$32 — —
Veozah
  • Astellas Pharma US Inc $29
$29 — —
ZAVZPRET
  • PFIZER INC. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record